Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kolykhalov I.V.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kalyn Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Roshchina I.F.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Odinak M.M.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Emelin A.Iu.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Kashin A.V.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Gustov A.V.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Antipenko E.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

SPIN RSCI: 7708-9068
Scopus AuthorID: 34871353400
ORCID: 0000-0002-8972-9150

Korshunova Iu.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Davydova T.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Messler G.

Ébeve Neĭro Farma GmbKh, Avstriia

Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment

Authors:

Gavrilova S.I., Kolykhalov I.V., Fedorova Ia.B., Selezneva N.D., Kalyn Ia.B., Roshchina I.F., Odinak M.M., Emelin A.Iu., Kashin A.V., Gustov A.V., Antipenko E.A., Korshunova Iu.A., Davydova T.A., Messler G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(1): 62‑69

Downloaded: 43

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Gavrilova SI, Kolykhalov IV, Fedorova IaB, et al. . Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(1):62‑69. (In Russ.)

Close metadata

Recommended articles:

Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):55-66

Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):42-51

Glymphatic dysfunction and sleep disorders: indirect effects on Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):7-12

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Comparative characteristics of neuropsychological and neurometabolic changes in patients with Alzheimer’s disease and vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):17-24

Impairment of attention and executive functions in chronic cerebrovascular disease and Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):25-32

Assessment of the significance of dilated perivascular spaces and nocture arterial hypertension in the development of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):33-40

EEG changes in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):72-76

Efficacy and safety of choline alfoscerate in the preventive therapy of dementia in elderly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99

Oxidative stress prevention as an effective preventive strategy in type 2 diabetes mellitus. Russian Journal of Preventive Medicine. 2024;(3):117-123

The study was conducted in 3 Russian centers (Moscow, St. Petersburg and Nizhniy Novgorod). The total sample included 110 patients whose mental state met the definition of «mild cognitive impairment» (MCI). Patient's status was assessed with widely used scales (MMSE, GDS, CDR etc) and a battery of neuropsychological tests. Genotyping for the APOE polymorphism was performed as well. Patients were stratified into 2 comparable groups in compliance with the specifics of therapy: 55 patients were treated with cerebrolysin and 55 - with cavinton. The superiority of cerebrolysin over cavinton in slowing down of the cognitive deficit progression and delaying the time or transition of patients to the diagnostic category of Alzheimer's disease was demonstrated. Cerebrolysin was particularly effective in MCI patients with the ApoE(+) genotype, i.e. in those with higher risk for Alzheimer's disease. Adverse effects during the treatment were rare in both groups.

Keywords:

mild cognitive impairment

Alzheimer's disease

preventive treatment

cerebrolysin

mild cognitive impairment

cavinton

Alzheimer's disease

preventive treatment

cerebrolysin

cavinton

mild cognitive impairment

Alzheimer's disease

preventive treatment

cerebrolysin

cavinton

Authors:

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kolykhalov I.V.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Kalyn Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Roshchina I.F.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Odinak M.M.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Emelin A.Iu.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Kashin A.V.

kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Gustov A.V.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Antipenko E.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

SPIN RSCI: 7708-9068
Scopus AuthorID: 34871353400
ORCID: 0000-0002-8972-9150

Korshunova Iu.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Davydova T.A.

kafedra nevrologii, neĭrokhirurgii i psikhiatrii TsPK i PPS Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Messler G.

Ébeve Neĭro Farma GmbKh, Avstriia

List of references:

Belousov Yu.B., Mednikov O.N., Chikina E.S. Farmakoekonomicheskie aspekty lecheniya dementsii v RF. Rus med zhurn 2005;13:20:1354.
Gavrilova S.I., Kolykhalov I.V., Selezneva N.D. i dr. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie vliyaniya tserebrolizina na effektivnost' i perenosimost' posleduyushchei kholinergicheskoi terapii u bol'nykh s bolezn'yu Al'tsgeimera. Sots i klin psikhiat 2000;2:41-46.
Gavrilova S.I., Kalyn Ya.B. Suitsidal'no-sredovye faktory i sostoyanie psikhicheskogo zdorov'ya pozhilogo naseleniya. Vestn RAMN 2002;9:15-20.
Gavrilova S.I. Neirotroficheskaya i neiroprotektivnaya terapiya. V kn.: Farmakoterapiya bolezni Al'tsgeimera. M: Pul's 2003;185-224.
Gavrilova S.I., Kolykhalov I.V., Korovaitseva G.I. i dr. AroE genotip i effektivnost' neirotroficheskoi i kholinergicheskoi terapii pri bolezni Al'tsgeimera. Zhurn nevrol i psikhiat 2005;105:4:27-33.
Gavrilova S.I., Fedorova Ya.B., Kolykhalov I.V. i dr. Terapevticheskii potentsial tserebrolizina v preventivnoi terapii bolezni Al'tsgeimera. Zhurn nevrol i psikhiat 2008;108:8:24-28.
Gavrilova S.I. Vozmozhnosti doklinicheskoi diagnostiki i preventivnogo terapevticheskogo vmeshatel'stva pri bolezni Al'tsgeimera. V kn.: Bolezn' Al'tsgeimera i kognitivnye narusheniya v pozhilom vozraste: dostizheniya v neirobiologii i terapii. M: Pul's 2008;6-32.
Gerasimov N.P. Dvoinoe slepoe platsebo-kontroliruemoe issledovanie effektivnosti tserebrolizina pri bolezni Al'tsgeimera. Sots i klin psikhiat 2000;2:35-40.
Kalyn Ya.B., Gavrilova S.I. Epidemiologicheskie i farmako-ekonomicheskie aspekty bolezni Al'tsgeimera. V kn.: Bolezn' Al'tsgeimera i kognitivnye narusheniya v pozhilom vozraste: dostizheniya v neirobiologii i terapii. M: Pul's 2008;275-285.
Alvares X.A., de Olano M., Sampedro C. et al. Cerebrolysin protect against neurodegeneration induced by β-amyloid implants in rats. Int J Neuropsychopharmac 2000;3:359.
Alvarez X.A., Lombardi V.R., Fernandez–Novoa L. et al. Cerebrolysin reduces microglial activation in-vivo and in-vitro: a potencial mechanism of neuroprotection. J Neurol Transm 2000;59:Suppl:281-292.
Alvares X.A., Cacabelos R., Laredo M. et al. A 24-week, double-blind, placebo-controlled study of dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006;13:43-54.
Chen Y., Tung Yu., Li B. et al. Trophic factor counteract elevated FGF-2 unduced inhibition of adult neurogenesis . Neurobiol Aging 2007;28:1148-1162.
Golomb J., Kluger A., Garrard P., Ferris S. Clinician's Manuel on Mild Cognitive Impairment. Science. London: Press Ltd 2001;56.
Gschanes A., Windish M. The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neurol Trasmis 1998;53:Suppl:
Low L.F., Anstey K.J. Dementia literacy: Recognition and Reliegs on Dementia of the Australian public. J Alzheimer's Dementia 2009;5:43-49.
Masliah E., Armasolo F., Veinberg I. et al. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behavior 1999;62:239-245.
Maslow K. How many people with dementia are hospitalized? In: Improving hospital care for persons with dementia. Eds. N.M. Silvertein, K. Maslow. New York: Springer 2006;3-21.
Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
Petersen R.C., Smith G.E., Waring S.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Int Med 2004;256:183-194.
Reinprecht I., Gschanes A., Windish M., Fachbach G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochemical J 1999;31:395-401.
Reisberg B., Ferris S.H., de Leon M.J. et al. The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia. Am J Psychiat 1982;139:1136-1139.
Ruther E., Ritter R., Apecechea M. et al. Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with senile dementia of the Alzheimer Type. Pharmacopsychiatry 1994;27:1:32-40.
Sallaw A., Mintzez J., Weiner M., Cummings J. Disease-modifying therapies in Alzheimer's disease. J Alzheimer's Dementia 2008;4:65-79.
Windisch M., Gschanes A., Hutter-Paier B. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neurol Transm 1998;Suppl 53:289-298.

Close metadata